✦ LIBER ✦

PMS5 Benefit-Risk Analysis of Adalimumab and Alternative Treatments for Moderate-to-Severe Rheumatoid Arthritis

✍ Scribed by K.A. Hicks; S.R. Earnshaw; J.W. Shaw; M. Cifaldi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS21 COST—EFFECTIVENESS OF RITUXIMAB VS

✍ LA Bynum; N Joshi 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Cost-effectiveness of adalimumab, etaner

✍ Soini, E. J.; Hallinen, T. A.; Puolakka, K.; Vihervaara, V.; Kauppi, M. J. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 418 KB

PMS31 Economic Evaluation of Adalimumab

✍ A. Marcellusi; N. Bansback; S. Rao; M. Cifaldi; L. Gitto; P. Giannantoni; S. Rus 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Adalimumab for treatment of moderate to

✍ M. R. Bongiorno; G. Pistone; S. Doukaki; M. Aricò 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 963 KB

PMS46 Cost-Utility Analysis of Certolizu

✍ R. Villoro; A. Hidalgo; B. Ferro; P. Talavera 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Comparison of benefit–risk profiles for

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB